Key Highlights

  • Shares finished 16.55% lower on November 17, 2026, a drop of about 16.6%, closing near USD 13.92.
  • YARTEMLEA brought in USD 35.9 million of net Revenue in the third quarter, short of the USD 37.3 million analysts had penciled in, though still 26% above the prior quarter.
  • A non-cash charge of USD 62.0 million, connected to the 2029 convertible notes, lifted the GAAP net loss to USD 57.4 million.
  • At the close of September, cash plus short-term investments amounted to USD 95.3 million.

Revenue Grows but Misses the Mark

Omeros (NASDAQ:OMER) built its recent narrative around narsoplimab, marketed as YARTEMLEA, its debut commercial product. Regulators approved it for transplant-associated thrombotic microangiopathy, a rare and frequently fatal complication that can develop after stem cell transplants. This launch has been the principal force behind the share price over the past year. Gross product sales during the third quarter climbed about 30% sequentially to USD 41.8 million, while net revenue advanced 26%, moving from USD 28.5 million up to USD 35.9 million. Deductions for rebates and discounts, measured against gross sales, increased to 14.0% from 11.5%, so a larger fraction never reached the company. Sequential progress is promising for a rare-disease product, though analysts were hoping for a stronger figure. The gap of roughly USD 1.4 million against consensus is small in dollar terms, yet for a company with one product the trajectory matters far more than any single quarter. Physician education and hospital formulary approvals usually make sales bounce around during the first year.

Non-Cash Charges Mask Healthier Operations

A GAAP net loss of USD 57.4 million, equal to USD 0.79 per share, appears daunting, but most of it never left the Business as cash. The company booked a USD 62.0 million charge on a derivative associated with the 2029 convertible notes, a valuation that swells when the stock rises. Setting those items aside, adjusted Net Income reached USD 4.7 million, or USD 0.06 per share, compared with USD 1.8 million a quarter earlier. Cash generated from operations came to USD 13.3 million, an important marker showing YARTEMLEA now funds day-to-day spending. Omeros also retired part of its 2029 notes, leaving approximately USD 40.3 million of principal owing. Medicare's new technology add-on, offering up to USD 287,079 for each qualifying inpatient case from October 1, ought to encourage hospitals to use the medication. Positive operating cash inflows also make a near-term share sale less likely, which had been an investor concern earlier in the launch.

European Setback and Upcoming Milestones

Pressure was not confined to North America. During October, a European advisory body recommended against the Marketing authorization after reviewing the file a second time, which constrains opportunities on that continent for some time. Uptake also depends on how fast transplant programs fold the therapy into routine protocols, because use in rare diseases tends to cluster among a few high-volume centres. Markets offered little help overall. The S&P 500 retreated 1.03%, while health care shares sold off after a proposed expansion of Medicare Advantage audits. Investors will focus on fourth-quarter sales, any widening of reimbursement and advances in the pipeline, including complement inhibitors for other conditions. Because the stock had surged in the months before the release, any letdown invited profit-taking, and a drop beyond 16% over a modest revenue gap reveals how much enthusiasm was already priced in. Turbulence should persist until two or three quarters of sales figures clarify the direction.

Where Things Stand

Omeros (NASDAQ:OMER) is expanding YARTEMLEA revenue and now produces positive operating cash flow, but a slim revenue shortfall and a European Reversal set off a heavy sell-off on November 17. Fourth-quarter results will show whether the launch keeps its strength. Cash generation and reduced Leverage give management time to demonstrate the case.